KEY POINTS
- Wall Street analysts project that Eli Lilly’s new weight-loss pill, Foundayo, could generate up to $2.8 billion in its first year.
- The oral medication offers significant manufacturing and storage advantages over traditional injectable treatments like Wegovy and Zepbound.
- Experts predict the global market for obesity pills will reach $60 billion annually by the end of the next decade.
Eli Lilly is preparing for a massive commercial launch of its newly approved obesity medication, Foundayo. Wall Street analysts expect the daily pill to become an immediate financial success upon its release. Forecasts for 2026 revenue range from $1.5 billion to $2.8 billion for the oral treatment.
The drug, known chemically as orforglipron, represents a major shift in the weight-management landscape. Unlike previous blockbuster treatments that require weekly injections, Foundayo is a simple daily tablet. This format appeals to patients who prefer to avoid needles for long-term chronic care.
Manufacturing advantages provide Eli Lilly with a significant edge in the competitive pharmaceutical market. Most current obesity drugs are biologics that require complex cold-chain storage and specialized glass syringes. Foundayo is a small-molecule drug that can be produced at a higher scale and lower cost.
Analysts from Citi suggest that peak annual sales for the pill could eventually exceed $40 billion. They believe the ease of distribution will allow the drug to reach international markets more quickly. This scalability addresses the chronic supply shortages that have hampered injectable treatments over the past two years.
The launch puts Eli Lilly in direct competition with rival Novo Nordisk. Novo recently introduced its own oral version of Wegovy to capture early adopters in the pill market. However, industry experts note that Lilly’s offering may have fewer dosing restrictions for patients.
Financial institutions like Bernstein and UBS are closely monitoring the initial rollout of the medication. They expect high prescription volumes but note that early revenue might be affected by introductory pricing strategies. The company intends to offer significant discounts to ensure broad insurance coverage and patient access.
Morningstar analysts predict that oral pills will eventually account for one-third of the entire obesity market. This transition could help the industry meet the surging global demand for metabolic health solutions. Many healthcare providers view pills as a more sustainable option for primary care settings.
Lilly has already invested billions into expanding its production facilities to support the Foundayo launch. The company aims to avoid the “unprecedented” supply hurdles that restricted sales of its injectable drug, Zepbound. Increased capacity remains a top priority for the Indianapolis-based pharmaceutical giant.
The entry of Foundayo is expected to reshape how doctors prescribe weight-loss therapy. Oral options allow for more flexible treatment plans and improved patient compliance over time. Clinical trials showed that the pill delivers weight-loss results comparable to many existing injectable medications.
Investors remain bullish on the long-term potential of the obesity drug sector. The combined sales of oral treatments from major manufacturers could reach $5 billion as early as next year. Eli Lilly appears well-positioned to lead this emerging class of cardiometabolic healthcare.
